A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Non-Small Cell Lung Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Peking Union Medical College Hospital, Beijing, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
Henan Provincial Cancer Hospital, Zhengzhou, China
Henan Provincial People's Hospital, Zhengzhou, China
Study leads
Junling Li
Principal Investigator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences